This piece is speculative analysis rather than a research note. The transactions are real; most of the consequences have not happened yet. In March 2026 Eli Lilly agreed to pay Insilico Medicine $115 million upfront, up to approximately $2.75 billion in development, regulatory and commercial milestones, and tiered royalties

Operating companies created twelve royalties this week and no fund bought one. Alteogen granted Novartis multiple options over subcutaneous formulations on its ALT-B4 hyaluronidase, up to $3,223M (KRW 4.4165 trillion) with royalties on top. HUTCHMED took $110M upfront within $1.295B from GSK and kept the Phase

Twenty-six mergers that will not happen, five that were mooted, and what each would do to the royalty streams underneath it

Athyrium Capital Management, LP is a New York healthcare investment manager formed in 2008 by Jeffrey A. Ferrell. It advises funds with more than $4.6B of committed capital across four vintages, and it describes its instrument set as royalties, structured credit, equities and select special situations. The royalties have

In one hundred days a platform company sold its royalty back to the licensee, sold the platform to a second buyer, and priced itself to a third at roughly the cash the first two produced. The two clinical assets went into a contingent right, carrying a royalty payable to Merck.

A stand-by licence is a licence granted at closing that sits dormant until a default or an insolvency wakes it.

Two years, forty-nine transactions, thirty-four structures. In 2025 the market did its volume in a converging form. In 2026 it wrote fifteen things it had not written the year before, and each one removes a specific blockage rather than adding a flourish.

Article 31(h) requires adequate remuneration in the circumstances of each case, taking into account the economic value of the authorisation. It does not name a base. Every issued licence of the last twenty years has resolved that silence the same way, and the resolution, rather than the headline rate,

The FDA approved RASONQUE on 26 Aug, starting royalty obligations under a Royalty Pharma synthetic royalty with $500M funded since May, and compelling the first $250M draw on a $750M term loan from the same counterparty. Rates run 4.55% to $2B of annual net sales, 2.50% to $4B,